A study in the British Journal of Cancer reports that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict treatment outcomes in advanced ovarian cancer following neoadjuvant chemotherapy. The research evaluates how imaging after NACT correlates with subsequent clinical response. The approach uses whole-body diffusion-weighted MRI, which measures how water motion changes across tissues—often interpreted as a proxy for cellular structure and tumor response. The report positions the imaging readout as a potential tool to support clinical decision-making after neoadjuvant regimens. For oncology teams, the reported emphasis is on improving prognostic stratification using imaging markers rather than relying solely on histopathology or limited-site assessments. The study’s results may inform how clinicians select next steps after chemotherapy response is established.